A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

113

Participants

Timeline

Start Date

September 10, 2020

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions
Locally Advanced or Metastatic Solid Tumors
Interventions
DRUG

SPYK04

SPYK04 capsule

Trial Locations (15)

22031

Virginia Cancer Specialists, Fairfax

22903

University of Virginia, Charlottesville

53226

Froedtert Hospital and the Medical College of Wisconsin, Milwaukee

55404

Minnesota Oncology, Minneapolis

75702

Texas Oncology, Tyler

77030

MD Anderson Cancer Center, Houston

80124

Rocky Mountain Cancer Centers, Lone Tree

85711

Arizona Oncology, Tucson

02903

Rhode Island Hospital, Providence

277-8577

National Cancer Center Hospital East, Kashiwa

830-0011

Kurume University Hospital, Kurume

104-0045

National Cancer Center Hospital, Chuo Ku

135-8550

Cancer Institute Hospital of Japanese Foundation for Cancer Research, Koto-Ku

811-1395

National Hospital Organization Kyushu Cancer Center, Fukuoka

541-8567

Osaka Prefectural Hospital Organization Osaka International Cancer Center, Osaka

Sponsors
All Listed Sponsors
lead

Chugai Pharmaceutical

INDUSTRY